. Author manuscript; available in PMC: 2014 Jan 24.

Published in final edited form as: Cancer Chemother Pharmacol. 2009 Feb 17;64(4):803–810. doi: 10.1007/s00280-009-0931-y

Table 4.

Toxicity

Treatment Related Toxicity (every 3 weeks)
Dose Level	# Patients	Myalgia	Nausea/vomiting	Fatigue	Headache	Neuropathy
		G1– 2/G3	G1–2/G3	G1– 2/G3	G1–2/G3	G1–2/3
1	3	0/0	2/0	0/0	0/0	0/0
2	3	0/0	1/0	1/0	1/0	0/0
3	3	0/0	2/0	2/0	0/0	0/0
4	3	0/0	1/0	1/0	0/0	1/0
5	3	0/0	1/0	1/0	0/0	0/0
6	3	0/0	2/1	1/0	0/0	1/0
7	3	0/0	3/0	0/0	2/0	1/0
8	3	0/0	1/0	2/0	1/0	0/0
9	3	0/0	1/1	3/0	0/0	0/0
10	6	1/1	3/0	3/0	0/0	0/0
11	6	2/2	2/0	2/0	0/0	0/0

Treatment Related Toxicity (every 2 weeks)
Dose Level	# Patients	Myalgia	Nausea/vomiting	Fatigue	Headache	Neuropathy
		G1– 2/G3	G1–2/G3	G1– 2/G3	G1–2/G3	G1–2/3
1A	6	1/3	3/3	4/2	0/1	0/0
2A	6	2/0	3/1	2/1	1/0	4/0